trending Market Intelligence /marketintelligence/en/news-insights/trending/V3E_l3q0hED-ildUv-rpEg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Aptevo's treatment for bone marrow cancer receives US FDA's orphan-drug tag

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Aptevo's treatment for bone marrow cancer receives US FDA's orphan-drug tag

The U.S. Food and Drug Administration has granted orphan-drug designation to Aptevo Therapeutics Inc.'s antibody treatment for acute myelogenous leukemia, or AML, a cancer of the blood and bone marrow.

The treatment, APVO436, works by binding to two cell receptors in the immune system, CD123 and CD3, to aid the body in detecting and fighting cancerous cells.

The treatment is being tested in a phase 1/1b clinical trial to test its effectiveness in fighting a group of cancers of the bone marrow, including AML, a rapidly progressing cancer originating from the production of dysfunctional blood cells in the body.

The orphan-drug designation encourages companies to develop cures for rare diseases by offering tax reductions, fee exemptions and a license to be the sole sellers of approved treatments for 7 years.

On Oct. 4, the company discontinued APVO210, its experimental drug for autoimmune diseases, after it failed to meet the desired product profile for commercialization in an early-stage study.